Notícias e Atividades da K36 Therapeutics

Fusão, aquisição e financiamento envolvendo K36 Therapeutics.

• K36 Therapeutics acaba de anunciar uma arrecadação de fundos de 70 milhões de dólares. (publicado em 30 de junho de 2023).

Veja o organograma con seus 14 executivos principais

Biografias mais buscadas da K36 Therapeutics

• Terrence Connolly, President and Chief Executive Officer
• Lori Kunkel, Independent Director
• Chong Xu, Director

Criar um alerta
para seguir os movimentos de executivos da K36 Therapeutics.

K36 Therapeutics possui 2.350 concorrentes concorrentes Astellas Gene Therapies (Estados Unidos), Eurofins (Luxemburgo) e Lonza (Suíça).

Popular M&A news in Biotecnologia

• Eli Lilly has announced the acquisition of Verve Therapeutics  (publicado em 17 de junho de 2025).
• Sirius Therapeutics acaba de anunciar uma arrecadação de fundos de 50 milhões de dólares. (publicado em 16 de junho de 2025).
• BioNTech has announced the acquisition of CureVac  (publicado em 12 de junho de 2025).

Outros contatos sugeridos na indústria do Biotecnologia

• Sandra Smith - Senior Vice President, Clinical Solutions & Strategic Partnerships da WIRB-Copernicus Group
• Jasbir Seehra - Chief Executive Officer and Chairman of the Board da Keros Therapeutics
• Deepika Verma - Associate Director of Data Science and Digitalization da Wheeler Bio

Saiba mais sobre a indústria do Biotecnologia

Últimos comunicados de imprensa de K36 Therapeutics

• K36 Therapeutics Announces Multiple Poster Presentations Highlighting the First Clinical Data for KTX-1001 and Other Developmental Compounds at the 66th American Society of Hematology (ASH) Annual Meeting
• K36 Therapeutics Announces Presentation on KTX-1001 for Relapsed and Refractory Multiple Myeloma at the 65th American Society of Hematology (ASH) Annual Meeting
• K36 Therapeutics Announces Appointment of Benjamin Winograd, MD, PhD, as Chief Medical Officer
• Yahooist Teil der Yahoo Markenfamilie
• Bristol Myers backs cancer startup K36 Therapeutics in $70M round - Boston Business Journal
• K36 Therapeutics Announces $70 Million Series B Financing to Fund Clinical Proof of Concept of KTX-1001, First-in-class Inhibitor of MMSET for Treatment of Multiple Myeloma Patients with Genetic Translocation (4;14)
• K36 doses first patient in Phase l multiple myeloma therapy trial
• View more press releases Close

Redes sociais sobre K36 Therapeutics

• K36 Therapeutics na Wikipedia, Google News e Yahoo Finance
• K36 Therapeutics na LinkedIn, Twitter e YouTube